hAPOC3
品系全名
C57BL/6JSmo-Apoc3tm1(hAPOC3)Smoc
目录号
NM-HU-225050
品系状态
活体
基因信息
基因名
Apoc3
品系描述
验证数据
Fig1. Detection of APOC3 expression in liver by RT-PCR.
Wild type: only one band at 196 bp with primers F1/R1(mApoc3);
Homozygous: only one band at 219 bp with primers F2/R2(hAPOC3).
Abbr. M, DNA marker; HO, homozygous; WT, wild type.
Fig2. Detection of species-specific APOC3 expression in serum by ELISA.
Abbr. HO, homozygous; HE, heterozygous; WT, wild type.
Fig3. Monitoring of blood lipids levels in hAPOC3 mice (n=3 female and 3 male).
Abbr. Hom, homozygous; WT, wild type.
Fig4. In Vivo Efficacy of APOC3 RNAi (ARO-APOC3) in hAPOC3 Mice.
hAPOC3 mice (male, 13 weeks old) were randomly divided into two groups(n=5/group). Mice were administered with ARO-APOC3, a nucleic acid drug targeting hAPOC3, synthesized according to the relevant patents. Blood lipids level of hAPOC3 mice before or after dosing were detected. Compared to vehicle, ARO-APOC3 treatment group showed a decrease in TG, T-CHO and LDL-C. Mean ± SEM. t-test, *P < 0.05, ***P < 0.001.
Fig5. In Vivo Efficacy of APOC3 RNAi (ARO-APOC3) in hAPOC3 Mice.
hAPOC3 mice (male, 13 weeks old) were randomly divided into two groups(n=5/group). Mice were administered with ARO-APOC3, a nucleic acid drug targeting hAPOC3, synthesized according to the relevant patents. At day 29 post-dosing, the mice were euthanized, and their livers were collected for the assessment of human APOC3 mRNA expression via qPCR. The results indicated a significant reduction in human APOC3 expression in the ARO-APOC3 treatment group compared to the vehicle control. Mean ± SEM. t-test.
Fig6. In Vivo Efficacy of APOC3 RNAi (ARO-APOC3) in hAPOC3 Mice.
hAPOC3 mice (male, 13 weeks old) were randomly divided into two groups(n=5/group). Mice were administered with ARO-APOC3, a nucleic acid drug targeting hAPOC3, synthesized according to the relevant patents. Expression level of hAPOC3 before or after dosing at indicated timepoint was detected by ELISA. Compared to vehicle, ARO-APOC3 treatment group showed a significant decrease in the expression of hAPOC3. Mean ± SEM. t-test, ***P < 0.001
你也可能感兴趣
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
查看Workshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
查看Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
查看
